Organigram Holdings Inc. (NASDAQ:OGI - Free Report) - Stock analysts at Atb Cap Markets issued their Q3 2025 earnings estimates for Organigram in a research note issued to investors on Wednesday, December 18th. Atb Cap Markets analyst F. Gomes anticipates that the company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Organigram's current full-year earnings is ($0.20) per share. Atb Cap Markets also issued estimates for Organigram's Q4 2025 earnings at ($0.01) EPS.
Organigram (NASDAQ:OGI - Get Free Report) last released its quarterly earnings results on Wednesday, December 18th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Organigram had a negative net margin of 45.57% and a negative return on equity of 16.76%.
Organigram Stock Up 6.8 %
Shares of OGI traded up $0.10 during trading hours on Friday, reaching $1.56. 1,093,492 shares of the company traded hands, compared to its average volume of 940,478. The stock has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $1.67. Organigram has a fifty-two week low of $1.21 and a fifty-two week high of $2.91. The stock has a market capitalization of $196.80 million, a PE ratio of -3.71 and a beta of 1.02.
Institutional Investors Weigh In On Organigram
A number of institutional investors have recently bought and sold shares of OGI. Tidal Investments LLC grew its position in Organigram by 8.3% during the third quarter. Tidal Investments LLC now owns 1,948,188 shares of the company's stock valued at $3,526,000 after acquiring an additional 149,171 shares during the period. AdvisorShares Investments LLC grew its holdings in shares of Organigram by 11.8% during the 2nd quarter. AdvisorShares Investments LLC now owns 1,000,126 shares of the company's stock worth $1,540,000 after purchasing an additional 105,468 shares during the period. Renaissance Technologies LLC increased its position in Organigram by 40.8% during the 2nd quarter. Renaissance Technologies LLC now owns 816,948 shares of the company's stock worth $1,258,000 after purchasing an additional 236,700 shares in the last quarter. Finally, Toronto Dominion Bank increased its position in Organigram by 803.7% during the 3rd quarter. Toronto Dominion Bank now owns 16,727 shares of the company's stock worth $30,000 after purchasing an additional 14,876 shares in the last quarter. 34.63% of the stock is currently owned by hedge funds and other institutional investors.
About Organigram
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Featured Articles
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
